329 related articles for article (PubMed ID: 19445363)
1. [Advances in sickle cell disease].
de Montalembert M
Bull Acad Natl Med; 2008 Oct; 192(7):1375-81; discussion 1381. PubMed ID: 19445363
[TBL] [Abstract][Full Text] [Related]
2. Pathophysiologically based drug treatment of sickle cell disease.
Steinberg MH
Trends Pharmacol Sci; 2006 Apr; 27(4):204-10. PubMed ID: 16530854
[TBL] [Abstract][Full Text] [Related]
3. Exciting new treatment approaches for pathyphysiologic mechanisms of sickle cell disease.
Mankad VN
Pediatr Pathol Mol Med; 2001; 20(1):1-13. PubMed ID: 12673841
[TBL] [Abstract][Full Text] [Related]
4. Overview of pathophysiology and rationale for treatment of sickle cell anemia.
Rodgers GP
Semin Hematol; 1997 Jul; 34(3 Suppl 3):2-7. PubMed ID: 9317195
[TBL] [Abstract][Full Text] [Related]
5. Sickle cell anemia: targeting the role of fetal hemoglobin in therapy.
Coleman E; Inusa B
Clin Pediatr (Phila); 2007 Jun; 46(5):386-91. PubMed ID: 17556734
[TBL] [Abstract][Full Text] [Related]
6. Mouse models of sickle cell disease.
Beuzard Y
Transfus Clin Biol; 2008; 15(1-2):7-11. PubMed ID: 18502677
[TBL] [Abstract][Full Text] [Related]
7. [Therapeutic perspectives of sickle cell anemia].
Beuzàrd Y
Rev Prat; 1992 Oct; 42(15):1908-11. PubMed ID: 1362468
[TBL] [Abstract][Full Text] [Related]
8. Effects of hydroxyurea on the membrane of erythrocytes and platelets in sickle cell anemia.
Covas DT; de Lucena Angulo I; Vianna Bonini Palma P; Zago MA
Haematologica; 2004 Mar; 89(3):273-80. PubMed ID: 15020264
[TBL] [Abstract][Full Text] [Related]
9. Therapy with hydroxyurea is associated with reduced adhesion molecule gene and protein expression in sickle red cells with a concomitant reduction in adhesive properties.
Gambero S; Canalli AA; Traina F; Albuquerque DM; Saad ST; Costa FF; Conran N
Eur J Haematol; 2007 Feb; 78(2):144-51. PubMed ID: 17313560
[TBL] [Abstract][Full Text] [Related]
10. Sickle cell disease: role of reactive oxygen and nitrogen metabolites.
Wood KC; Granger DN
Clin Exp Pharmacol Physiol; 2007 Sep; 34(9):926-32. PubMed ID: 17645642
[TBL] [Abstract][Full Text] [Related]
11. Pathophysiology and treatment of sickle cell disease.
Raphael RI
Clin Adv Hematol Oncol; 2005 Jun; 3(6):492-505. PubMed ID: 16167028
[TBL] [Abstract][Full Text] [Related]
12. [Pathophysiology and treatment of sickle-cell disease].
van Beers EJ; Peters M; Biemond BJ
Ned Tijdschr Geneeskd; 2005 May; 149(21):1144-9. PubMed ID: 15940917
[TBL] [Abstract][Full Text] [Related]
13. Genetic correction of sickle cell disease: insights using transgenic mouse models.
Blouin MJ; Beauchemin H; Wright A; De Paepe M; Sorette M; Bleau AM; Nakamoto B; Ou CN; Stamatoyannopoulos G; Trudel M
Nat Med; 2000 Feb; 6(2):177-82. PubMed ID: 10655106
[TBL] [Abstract][Full Text] [Related]
14. [Clinical trials of new therapeutic pharmacology for sickle cell disease].
Brugnara C; de Franceschi L
Sante; 2006; 16(4):263-8. PubMed ID: 17446160
[TBL] [Abstract][Full Text] [Related]
15. Pharmacologic induction of fetal hemoglobin synthesis: cellular and molecular mechanisms.
Yang YM; Pace B
Pediatr Pathol Mol Med; 2001; 20(1):87-106. PubMed ID: 12673846
[TBL] [Abstract][Full Text] [Related]
16. Hydroxyurea in sickle cell disease--a study of clinico-pharmacological efficacy in the Indian haplotype.
Italia K; Jain D; Gattani S; Jijina F; Nadkarni A; Sawant P; Nair S; Mohanty D; Ghosh K; Colah R
Blood Cells Mol Dis; 2009; 42(1):25-31. PubMed ID: 18954999
[TBL] [Abstract][Full Text] [Related]
17. Hydroxyurea therapy: improving the lives of patients with sickle cell disease.
Anderson N
Pediatr Nurs; 2006; 32(6):541-3. PubMed ID: 17256291
[TBL] [Abstract][Full Text] [Related]
18. Established and experimental treatments for sickle cell disease.
De Franceschi L; Corrocher R
Haematologica; 2004 Mar; 89(3):348-56. PubMed ID: 15020275
[TBL] [Abstract][Full Text] [Related]
19. [Advances. New treatment for sickle cell anemia].
de Montalembert M
Med Trop (Mars); 1998; 58(2):117-9. PubMed ID: 9791585
[No Abstract] [Full Text] [Related]
20. Increased adhesive properties of neutrophils in sickle cell disease may be reversed by pharmacological nitric oxide donation.
Canalli AA; Franco-Penteado CF; Saad ST; Conran N; Costa FF
Haematologica; 2008 Apr; 93(4):605-9. PubMed ID: 18326523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
